Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

New Agents

Research into new physical or chemical means to treat disease.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
INTRODUCTION The sequential use of a number of new agents (NAs) have improved the overall survival (OS) of patients with… Expand
2018
2018
323Background: Until few years ago, docetaxel (DOC) was the only agent able to significantly prolong overall survival (OS) of… Expand
2017
2017
5030Background: Abiraterone acetate (AA), cabazitaxel (CABA), and enzalutamide (ENZ) may prolong survival in mCRPC pts… Expand
Review
2015
Review
2015
BACKGROUND Two new hormonal agents (NHAs), abiraterone and enzalutamide, and one chemotherapeutic agent, cabazitaxel (CABA… Expand
2015
2015
258 Background: NAs have recently demonstrated a survival advantage in mCRPC pts progressing after DOC: two hormonal NAs (HNA… Expand
2014
2014
The use of new agents (NAs) such as bortezomib, thalidomide, and lenalidomide has extended the survival of patients with multiple… Expand
Review
2014
Review
2014
  • B. Rovin, S. Parikh
  • American journal of kidney diseases : the…
  • 2014
  • Corpus ID: 8607075
Immune complex accumulation in the kidney is the hallmark of lupus nephritis and triggers a series of events that result in… Expand
  • figure 1
  • table 1
  • figure 2
Highly Cited
2013
Highly Cited
2013
Therapy-related acute myeloid leukemia (tAML) is a rare but highly fatal complication of cytotoxic chemotherapy. Despite major… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
2012
2012
  • A. Badros
  • The New England journal of medicine
  • 2012
  • Corpus ID: 45266721
With the introduction of high-dose therapy and new agents, outcomes of treatment have improved considerably for patients with… Expand
1984
1984
  • D. Sachar
  • The American journal of gastroenterology
  • 1984
  • Corpus ID: 22468260
Treatment programs for digestive diseases should be evaluated by randomized clinical trials. Under most circumstances, the best… Expand